Navigating the Evolving Paradigm in Heart Failure

The Emerging Impact of SGLT2 Inhibition

Thursday, October 1, 2020
Virtual Symposium
4:30 PM–5:45 PM EDT

FACULTY

Javed Butler, MD, MPH, MBA
Activity Chair
University of Mississippi
Jackson, Mississippi

Suzanne V. Arnold, MD, MHA
Saint Luke’s Mid America Heart Institute
Kansas City, Missouri

John McMurray, MD
University of Glasgow
Glasgow, Scotland, UK

Muthiah Vaduganathan, MD, MPH
Harvard Medical School
Boston, Massachusetts

AGENDA all times EDT

4:30 PM–4:35 PM Welcome and Introductions/Pre-test
Javed Butler, MD, MPH, MBA (Activity Chair)

4:35 PM–4:50 PM A Review of Cardiovascular Outcomes Trial (CVOT) Data: Exploring the Pivotal Link Between T2D and HF
Suzanne V. Arnold, MD, MHA

4:50 PM–5:15 PM Stepping Beyond the Status Quo: How SGLT2 Inhibitors are Bridging the Chasm in Heart Failure
Javed Butler, MD, MPH, MBA
John McMurray, MD

5:15 PM–5:35 PM Revolutionizing Heart Failure Outcomes: Meeting Complex Clinical Challenges through Strategic Collaboration
Muthiah Vaduganathan, MD, MPH

5:35 PM–5:45 PM Conversations with the Experts/Audience Q&A/Post-test
All Faculty

ACCREDITATION

In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Heart Failure Society of America designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Presented by Creative Educational Concepts, Inc.
Supported through an independent educational grant from AstraZeneca.

This satellite symposium is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.